references -...
TRANSCRIPT
207
REFERENCES
1. Ogsten A (1881). Report upon microorganisms in surgical diseases. Br Med J
1:369-375.
2. Rosenbach FJ (1884). Mikro-Organismen bei den Wund-Infektions-Krankenheiten
des Menschen. Wiebaden. J.F. Bergmann’s Verlag.
3. Lowy FD (1998). Staphylococcus aureus infections. N Engl J Med 339:520-532.
4. Boucher H, Miller LG, Razonable RR (2010). Serious infections caused by
methicillin-resistant Staphylococcus aureus. Clin Infect Dis 51(S2):S183-S197.
5. Boucher HW, Corey GR (2008). Epidemiology of methicillin-resistant
staphylococcus aureus. Clin Infect Dis 46:S344-9.
6. David MZ, Daum RS (2010). Community-associated methicillin-resistant
Staphylococcus aureus: Epidemiology and clinical consequences of an emerging
epidemic. Clin Microbiol Rev 23(No. 3):616-687.
7. Chug TD (2007). Staphylococcus aureus: the modern Ghengis Khan. J Infect
Developing Countries 1(2):125-128.
8. Brooks GF, Carroll KC, Butel JS, and Morse SA. (2007). Jawetz, Melnick, &
Adelberg's Medical Microbiology, 24th edition, New York: McGraw-Hill Medical.
9. Juhasz-Kaszanyitzky E, Janosi S, Somogyi P, Dan A, Bloois L, Duijkeren E,
Wagenaar JA (2007) MRSA transmission between cows and humans. Emerg Infect
Dis 13:630-632.
10. Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM (2006). A study of the
relationship between environmental contamination with methicillin-resistant
208
Staphylococcus aureus (MRSA) and patients’ acquisition of MRSA. Infect Control
Hosp Epidemiol 27:127-132.
11. Scott E, Duty S, Callahan M (2008). A pilot study to isolate Staphylococcus aureus
and methicillin-resistant S. aureus from environmental surfaces in the home. Am J
Infect Control 36:458-460.
12. Tolba O, Loughrey A, Goldsmith CE, Millar BC, Rooney PJ, Moore JE (2007).
Survival of epidemic strains of nosocomial and community-acquired methicillin-
resistant Staphylococcus aureus on coins. Am J Infect Control 35:342-346.
13. Kumari DNP, Haji TC, Keep V, Hawkey PM, Duncanson V, Flower E (1998).
Ventilation grilles as a potential source of methicillinresistant Staphylococcus
aureus causing an outbreak in an orthopaedic ward at a district general hospital. J
Hosp Infect 39:127-133.
14. Cotterill S, Evans R, Fraise AP (1996). An unusual source for an outbreak of
methicillin-resistant Staphylococcus aureus on an intensive therapy unit. J Hosp
Infect 32:207-216.
15. Blythe D, Keenlyside D, Dawson SJ, Galloway A (1998). Environmental
contamination due to methicillin-resistant Staphylococcus aureus (MRSA). J Hosp
Infect 38:67-70.
16. Aminov RI (2010). A brief history of the antibiotic era: lessons learned and
challenges for the future. Front Microbiol 1:134. doi: 10.3389/fmicb.2010.00134.
17. Yanling J, Xin L, Zhiyuan L (2013). The antibacterial drug discovery. In El-Shemy
HA (ed). Drug Discovery. pp. 289-307. Janeza Trdine 9, 51000 Rijeka, Croatia.
InTech.
18. Heynick F (2009). The original 'magic bullet' is 100 years old-extra. Br J
Psychiatry 195(5):456-469.
209
19. Mahoney JE, Arnold RC, Harris A (1943). Penicillin Treatment of Early Syphilis-
A Pre‐liminary Report. Am J Public Health Nations Health 33(12):1387-1391.
20. Fleming A (1929). On the antibacterial action of cultures of a Penicillium, with
special reference to their use in the isolation of B. influenzae. British Journal of
Experimental Pathology. 10: 226-236.
21. Duchesne (1897). Antagonism between molds and bacteria. An English translation
by Michael Witty. Fort Myers, 2013. ASIN B00E0KRZ0E and B00DZVXPIK.
22. Chain E. Florey HW, Adelaide MB, Gardner AD, Heatley NG (1940). Penicillin as
chemotherapeutic agent. Lancet 1:1172.
23. Fletcher C (1984). First clinical use of penicillin. Br Med J 289:1721-1723.
24. Straand J, Gradmann C, Lindbæk M, Simonsen GS (2008). Antibiotic development
and resistance. In: International Encyclopedia of Public Health. pp 200-211.
Academic Press, Oxford.
25. Kirby WM (1944). Extraction of a highly potent penicillin inactivator from
penicillin resistant Staphylococci. Science 99:452-453.
26. Barber M, Rozwadowska-Dowzenko M (1948). Infection by penicillin-resistant
staphylococci. Lancet 252:641-644.
27. Abraham EP, Chain E (1940). An enzyme from bacteria able to destroy penicillin.
Nature 146:387.
28. Abboud FM, and Waisbren BA (1959). Correlation between in vitro studies and
response to antibiotic therapy in staphylococcic bacteremia. Archives of Internal
Medicine 104(2):226-233.
29. Fleming A. Penicillin. Nobel lecture, December 11, 1945. Available from:
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-
lecture.pdf. Accessed on 12 September 2013.
210
30. Reynolds L, Tansey E (2008). Superbugs and Superdrugs: A History of
MRSA. London: Wellcome Trust. Available from:
http://www.history.qmul.ac.uk/research/modbiomed/Publications/wit_vols/44862.p
df. Accessed on 10 September 2013.
31. Dowling HF (1961). The newer penicillins. Clin Pharmacol Ther 2:572-580.
32. Barber M (1961). Methicillin-resistant staphylococci. J Clin Pathol 14:385-393.
33. Jevons M (1961). “Celbenin”-resistant staphylococci. Br Med J 1:124-125.
34. Parker MT, Jevons MP (1964). A survey of methicillin resistance
in Staphylococcus aureus. Postgrad Med J 40:170-8.
35. Brumfitt W, Hamilton-Miller J (1989). Methicillin-resistant Staphylococcus
aureus. New Engl J Med 320:1188-1196.
36. Casewell MW (1986). Epidemiology and control of the ‘modern’ methicilin-
resistant Staphylococcus aureus. J Hosp Infect 7:1.
37. Chambers HF, Deleo FR (2009) Waves of resistance: Staphylococcus aureus in the
antibiotic era. Nature Reviews Microbiology 7:629‐641.
38. Weinstein RA (2003). “Antibiotic Resistance in Hospitals and Intensive Care
Units: the Problem and Potential Solutions. Seminars in Respiratory and Critical
Care Medicine 24(1): 113-20.
39. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997). Methicillin
resistant Staphylococcus aureus clinical strain with reduced vancomycin
susceptibility. J Antimicrob Chemother 40:135‐136.
40. Centers for Disease Control and Prevention (2002). Staphylococcus aureus
resistant to vancomycin – United States, 2002. Morbidity and Mortality Weekly
Report MMWR 51:565‐567.
211
41. Song JH, Hiramatsu K, Suh JY, et al. (2004). Asian network for surveillance of
resistant pathogens study group: Emergence in Asian countries of Staphylococcus
aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother
48:4926‐ 4928.
42. Centers for Disease Control and Prevention (2004). Vancomycinresistant
Staphylococcus aureus New York, 2004. Morbidity and Mortality Weekly Report
MMWR 53:322‐323.
43. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP (1998).
Vancomycin‐resistant Staphylococcus aureus. Lancet 351:602.
44. Assadullah S, Kakru DK, Thoker MA, Bhat FA, Hussain N, Shah A (2003).
Emergence of low level vancomycin resistance in MRSA. Indian J Med Microbiol
21:196‐198.
45. Tiwari HK and Sen MR (2006). Emergence of vancomycin resistant
Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of
India. BMC Infect Dis 6:156.
46. Menezes GA, Harish BN, Sujatha S, Vinothini K, Parija SC (2008). Emergence of
vancomycin‐intermediate Staphylococcus species in southern India. J Med
Microbiol 57:911‐912.
47. Thati V, Channappa T, Shivannar T,Gaddad SM (2011) Vancomycin resistance
among methicillin resistant Staphylococcus aureus isolates from intensive care
units of tertiary care hospitals on Hyderabad. Indian J Med Res 134:704‐708.
48. Tsiodras S, Gold HS, Sakoulas G, et al. (2001). Linezolid resistance in a clinical
isolate of Staphylococcus aureus. Lancet 358:207-208.
212
49. Ross JE, Farrell DJ, Mendes RE, Sader HS, Jones RN (2011). Eight-year (2002-
2009) summary of the linezolid program in European countries. J Chemother
23:71-76.
50. Peer MA, Nasir RA, Kakru DK, Fomda BA, Bashir G, Sheikh IA (2011). Sepsis
due to linezolid resistant Staphylococcus cohniiand Staphylococcus kloosii: First
reports of linezolid resistance in coagulase negative staphylococci from India.
Indian J Med Microbiol 29:60-62.
51. World Health Organization. Antimicrobial resistance. Available from:
http://www.who.int/mediacentre/factsheets/fs194/en/. Accessed on 12 September
2013.
52. Deasy J (2009). Antibiotic resistance: The ongoing challenge for effective drug
therapy. JAAPA 22(3):18‐22.
53. Gould IM (2006). Costs of hospital-acquired methicillin-resistant Staphylococcus
aureus (MRSA) and its control. Int J Antimicrob Agents 28:379-384.
54. Klein E, Smith DL, Laxminarayan R (2007). Hospitalizations and deaths caused by
methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg
Infect Dis 13:1840-1846.
55. Köck R, Becker K, Cookson B, et al. (2010). Methicillin-resistant Staphylococcus
aureus (MRSA): Burden of disease and control challenges in Europe. Euro
Surveill 15:196-88.
56. Skinner D and Keefer CS (1941). Significance of bacteremia caused by
Staphylococcus aureus. Archives of Internal Medicine 68:851-875.
57. Green BN, Johnson CD, Egan JT, et al. (2012). Methicillin-resistant
Staphylococcus aureus: an overview for manual therapists. Journal of Chiropractic
Medicine 11:64-76.
213
58. Cosgrove SE, Carmeli Y (2003). The impact of antimicrobial resistance on health
and economic outcomes. Clin Infect Dis 36:1433-7.
59. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y (2005). The
impact of methicillin resistance in Staphylococcus aureus bacteremia on patient
outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp
Epidemiol 26:166-74.
60. McHugh CG, Riley LW (2004). Risk factors and costs associated with methicillin-
resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp
Epidemiol 25:425–30.
61. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A (1999).
The economic impact of Staphylococcus aureus infection in New York City
hospitals. Emerg Infect Dis 5:9–17.
62. Cassell GH and Mekalanos J (2001). Development of antimicrobial agents in the
era of new and reemerging infectious diseases and increasing antibiotic resistance.
Journal of the American Medical Association 285:601-605.
63. Alanis AJ (2005). Resistance to antibiotics: Are we in the post-antibiotic era?
Archives of Medical Research 36:697-705.
64. Kahrstrom CT (2013). Entering a post-antibiotic era? Nat Rev Microbiol 11:146.
65. Joshi S (2010). Hospital antibiogram: A necessity. Indian J Med Microbiol
28(4):277-280.
66. Horvat RT (2010). Review of antibiogram preparation and susceptibility testing
systems. Hosp Pharm 45(11 Suppl 1):S6–S9. Thomas Land Publishers, Inc.
www.thomasland.com
214
67. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for
Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. Vol.
30. Wayne, Pennsylvania: Author; 2010. CLSI/NCCLS document M100-S20.
68. Clinical and Laboratory Standards Institute (CLSI). Analysis and Presentation of
Cumulative Susceptibility Test Data: Approved Guideline. Wayne, Pennsylvania:
CLSI; 2006. CLSI document M39-A2.
69. Wikipedia. The Free Encyclopaedia. Bastar district. Available from:
http://en.wikipedia.org/wiki/Bastar_district. Accessed on 14 September 2013.
70. Human development report Chattisgarh. Available from:
http://chhattisgarh.nic.in/book/hdr.pdf. Accessed on 14 September 2013.
71. District censos 2011. Available from: http://www.census2011.co.in/district.php.
Accessed on 14 September 2013.
72. US Directorate of Intelligence. "Country Comparison: Population". "Swaziland
1,403,362" Available from: https://www.cia.gov/library/publications/the-world-
factbook/rankorder/2119rank.html. Accessed on 14 September 2013.
73. United States Census 2010. 2010 Interactive Population Search “Hawaii” “Total
Population: 1,360,301” Available from:
http://www.census.gov/2010census/popmap/ipmtext.php?fl=15. Accessed on 14
September 2013.
74. Lewis MP (2009). "Bhatri: A language of India". Ethnologue: Languages of the
World, 16th edition. Dallas, Texas: SIL International.
75. Chopra K, Makol N (2004) Common health problems encountered by the tribal
community in Bastar district. Health and Population‐Perspective Issues 27:40‐48.
http://www.nihfw.org/Publications/material/J513.pdf.
215
76. Greenwood D, Slack R, Peutherer J, Barer M (2008). Medical Microbiology. A
guide to microbial infections: Pathogenesis, immunity, laboratory diagnosis and
control, 7th
edition. Churchill Livingstone, Elsvier Limited.
77. Cotran RS, Kumar V, Collins T (1999). Robbins pathologic basis of disease. 6th
edition. Philadelphia, WB Saunders Company.
78. Dissemond J (2009). Methicillin resistant Staphylococcus aureus (MRSA):
diagnostic, clinical relevance and therapy. J Dtsch Dermatol Ges 7(6):544-51.
79. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA (2002). Medical
Microbiology, 4th edition, Mosby.
80. Durai R, Ng PC, Hoque H (2010). Methicillin-resistant Staphylococcus aureus: an
update. AORN J 91(5):599-606.
81. Paniker CKJ (ed.) (2006). Ananthanarayan and Paniker’s Textbook of
Microbiology, 7th
edition, Orient Longman Private Limited.
82. Collee JG, Duguid JP, Fraser AG, Marmion BP (eds.) (1989). Mackie &
McCartney Practical Medical Microbiology, 13th
edition, Volume 2 of Medical
Microbiology. Longman Group UK, Churchill Livingstone.
83. Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods G
(eds.) (2006). Koneman’s Color Atlas and Textbook of Diagnostic Microbiology,
6th
edition, Lippincott Williams & Wilkins, Baltimore, USA.
84. Inweregbu K, Dave J, Pittard A (2005). Nosocomial infections. Cont Edu Anaesth
Crit Care & Pain 5:14-17.
85. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. (2008).
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-
associated infections: annual summery of data reported to the National Healthcare
216
Safety Network at the Centers for Disease Control and Prevention, 2006-2007.
Infect Control Hosp Epidemiol 29:996-1011.
86. Berglund C, Söderquist B (2008). The origin of a methicillin-resistant
Staphylococcus aureus isolate at a neonatal ward in Sweden—possible horizontal
transfer of a staphylococcal cassette chromosome mec between methicillin-resistant
Staphylococcus haemolyticus and Staphylococcus aureus. Clin Microbiol Infect
14:1048–1056.
87. Buckingham SC, McDougal LK, Cathey LD, Comeaux K, Craig AS, Fridkin SK,
Tenover FC (2004). Emergence of community acquired methicillin-resistant
Staphylococcus aureus at a Memphis, Tennessee children’s hospital. Pediatr Infect
Dis J 23:619-624.
88. Munckhof WJ, Nimmo GR, Carney J, Schooneveldt JM, Huygens F, Inman-
Bamber J, Tong E, Morton A, Giffard P (2008). Methicillin susceptible, non-
multidrug resistant and multidrug resistant methicillin-resistant Staphylococcus
aureus infections: a clinical, epidemiological and microbiological comparative
study. Eur J Clin Microbiol Infect Dis 27:355-364.
89. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J,
Johnson SK, Vadenesch F, Fridkin S, O’Boyle C, Danila RN, Lynfield R (2003).
Comparison of community- and health care-associated methicillin resistant
Staphylococcus aureus infection. JAMA 290:2976-2984.
90. Costerton JW, Stewart PS, et al. (1999). Bacterial biofilms: a common cause of
persistent infections. Science 284(5418):1318-1322.
91. Götz F (2002). Staphylococcus and biofilms. Mol Microbiol 43(6):1367-1378.
92. Otto M (2008). Staphylococcal biofilms. Curr Top Microbio Immunol 322:207-
228.
217
93. Archer GL (1998). Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis
26(5):1179-1181.
94. Mazmanian SK, Liu G, Ton-That H, Schneewind O (1999). Staphylococcus
aureus sortase, an enzyme that anchors surface proteins to the cell
wall. Science 285:760-763.
95. Patti JM, Allen BL, McGavin MJ, Hook M (1994). MSCRAMM-mediated
adherence of microorganisms to host tissues. Annu Rev Microbiol 48:585-617.
96. Gordon RJ, Lowy FD (2008). Pathogenesis of methicillin-resistant Staphylococcus
aureus infection. Clin Infect Dis 46:S350-S359.
97. Foster TJ, Hook M (1998). Surface protein adhesins of Staphylococcus aureus.
Trends Microbiol 6:484-488.
98. Menzies BE (2003). The role of fibronectin binding proteins in the pathogenesis of
Staphylococcus aureus infections. Curr Opin Infect Dis 16:225-229.
99. Tung H, Guss B, Hellman U, Persson L, Rubin K, Ryden C (2000). A bone
sialoprotein-binding protein from Staphylococcus aureus: a member of the
staphylococcal Sdr family. Biochem J 345:611-619.
100. Donlan RM, Costerton JW (2002). Biofilms: survival mechanisms of clinically
relevant microorganisms. Clin Microbiol Rev 15:167-193.
101. Ogawa SK, Yurberg ER, Hatcher VB, Levitt MA, Lowy FD (1985). Bacterial
adherence to human endothelial cells in vitro. Infect Immun 50:218-224.
102. Hamill RJ, Vann JM, Proctor RA (1986). Phagocytosis of Staphylococcus aureus
by cultured bovine aortic endothelial cells: model for postadherence events in
endovascular infections. Infect Immun 54:833-836.
218
103. Arrecubieta C, Lowy FD (2006). Staphylococcus aureus–eukaryotic cell
interactions. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI (eds.)
Gram-positive pathogens. 2nd
edition, pp. 517-525. Washington, DC, ASM Press.
104. Moreillon P, Que YA, Bayer AS (2002). Pathogenesis of streptococcal and
staphylococcal endocarditis. Infect Dis Clin North Am 16:297-318.
105. Kahl B, Herrmann M, Everding AS, et al (1998). Persistent infection with small
colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J
Infect Dis 177:1023-1029.
106. Proctor RA, Peters G (1998). Small colony variants in staphylococcal infections:
diagnostic and therapeutic implications. Clin Infect Dis 27:419-422.
107. Proctor RA, van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD (1995).
Persistent and relapsing infections associated with small-colony variants of
Staphylococcus aureus. Clin Infect Dis 20:95-102.
108. Foster TJ (2005). Immune evasion by staphylococci. Nat Rev Microbiol 3:948-958.
109. O’Riordan K, Lee JC (2004). Staphylococcus aureus capsular polysaccharides.
Clin Microbiol Rev 17:218-234.
110. Tzianabos AO, Wang JY, Lee JC (2001). Structural rationale for the modulation of
abscess formation by Staphylococcus aureus capsular polysaccharides. Proc Natl
Acad Sci USA 98:9365-9370.
111. Deisenhofer J (1981). Crystallographic refinement and atomic models of a human
Fc fragment and its complex with fragment B of protein A from Staphylococcus
aureus at 2.9- and 2.8-A resolution. Biochemistry 20:2361-2370.
112. Gladstone GP, VanHeyningen WE (1957). Staphylococcal leucocidins. Br J Exp
Pathol 38:123-137.
219
113. Timmerman CP, Mattsson E, Martinez-Martinez L, et al. (1993). Induction of
release of tumor necrosis factor from human monocytes by staphylococci and
staphylococcal peptidoglycans. Infect Immun 61:4167-4172.
114. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A (1994). Grampositive
cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by
human monocytes. Infect Immun 62:2715-2721.
115. Bhakdi S, Tranum-Jensen J (1991). Alpha-toxin of Staphylococcus aureus.
Microbiol Rev 55:733-751.
116. Dinges MM, Orwin PM, Schlievert PM (2000). Exotoxins of Staphylococcus
aureus. Clin Microbiol Rev 13:16-34.
117. McCormick JK, Yarwood JM, Schlievert PM (2001). Toxic shock syndrome and
bacterial superantigens: an update. Annu Rev Microbiol 55:77-104.
118. Prevost G, Couppie P, Monteil H (2003). Staphylococcal epidermolysins. Curr
Opin Infect Dis 16:71-76.
119. Yarwood JM, Schlievert PM (2003). Quorum sensing in Staphylococcus infections.
J Clin Invest 112:1620-1625.
120. Novick RP (2003). Autoinduction and signal transduction in the regulation of
staphylococcal virulence. Mol Microbiol 48:1429-1449.
121. Cheung AL, Eberhardt KJ, Chung E, et al. (1994). Diminished virulence of a
sar−/agr
− mutant of Staphylococcus aureus in the rabbit model of endocarditis. J
Clin Invest 94:1815-1822.
122. Cheung AL, Koomey JM, Butler CA, Projan SJ, Fischetti VA (1992). Regulation
of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from
agr. Proc Natl Acad Sci USA 89:6462-6466.
220
123. Fournier B, Hooper DC (2000). A new two-component regulatory system involved
in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus
aureus. J Bacteriol 182:3955-3964.
124. Liang X, Yu C, Sun J, et al. (2006). Inactivation of a two-component signal
transduction system, SaeRS, eliminates adherence and attenuates virulence of
Staphylococcus aureus. Infect Immun 74:4655-4665.
125. Giraudo AT, Cheung AL, Nagel R (1997). The sae locus of Staphylococcus aureus
controls exoprotein synthesis at the transcriptional level. Arch Microbiol 168:53-
58.
126. Said-Salim B, Dunman PM, McAleese FM, et al. (2003) Global regulation of
Staphylococcus aureus genes by Rot. J Bacteriol 185:610-619.
127. Luong TT, Newell SW, Lee CY (2003). Mgr, a novel global regulator in
Staphylococcus aureus. J Bacteriol 185:3703-3710.
128. Willey JM, Sherwood L & Woolverton CJ (2011). Prescott, Harley, and Klein's
Microbiology, 8th edition, New York: McGraw-Hill Higher Education.
129. Winston LG, Chambers HF (2009). Antimicrobial resistance in staphylococci:
Mechanisms of resistance and clinical implications. In Mayers DL (ed)
Antimicrobial Drug Resistance. Clinical and epidemiological aspects. Vol. 2. pp.
735-748. Humana Press.
130. Lowy FD (2003). Antimicrobial resistance: the example of Staphylococcus aureus.
J Clin Invest 111(9):1265-1273.
131. Kernodle DS (2000). Mechanisms of resistance to β-lactam antibiotics. In Gram-
positive pathogens. Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, and Rood JI,
(eds). American Society for Microbiology. Washington, DC, USA. 609-620.
221
132. Gregory, PD, Lewis, RA, Curnock, SP, Dyke, KG (1997). Studies of the repressor
(BlaI) of beta-lactamase synthesis in Staphylococcus aureus. Mol
Microbiol 24:1025-1037.
133. Zhang, HZ, Hackbarth, CJ, Chansky, KM, Chambers, HF (2001). A proteolytic
transmembrane signaling pathway and resistance to beta-lactams in
staphylococci. Science 291:1962-1965.
134. Pinho M, Filipe S, de Lencastre H, Tomasz A (2001). Complementation of the
essential peptidoglycan transpeptidase function of penicillin-binding protein 2
(PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J.
Bacteriol. 183, 6525-6531.
135. Pinho MG, de Lencastre H, Tomasz A (2001). An acquired and a native penicillin-
binding protein cooperate in building the cell wall of drug-resistant staphylococci.
Proc Natl Acad Sci USA 98:10886-10891.
136. Walsh TR, and Howe RA (2002). The prevalence and mechanisms of vancomycin
resistance in Staphylococcus aureus. Annu Rev Microbiol 56:657-675.
137. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover F (1997). Methicillin-
resistant Staphylococcus aureus clinical strain with reduced vancomycin
susceptibility. J Antimicrob Chemother 40:135-136.
138. Liu C, Chambers H (2003). Staphylococcus aureus with heterogeneous resistance
to vancomycin: epidemiology, clinical significance, and critical assessment of
diagnostic methods. Antimicrob Agents Chemother 47:3040-3045.
139. Hiramatsu K, Aritaka N, Hanaki H et al. (1997). Dissemination in Japanese
hospitals of strains of Staphylococcus aureus heterogeneously resistant to
vancomycin. Lancet 350:1670-1673.
222
140. Bobin-Dubreux S, Reverdy ME, Nervi C et al. (2001). Clinical isolate of
vancomycin heterointermediate Staphylococcus aureus susceptible to methicillin
and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents
Chemother 45:349-352.
141. Rybak MJ, Cha R, Cheung CM, Meka VG, Kaatz GW (2005): Clinical isolates of
Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous
resistance to vancomycin and teicoplanin. Diagn Microbio. Infect Dis 51:119-125.
142. Sieradzki K, Tomasz A (1997): Inhibition of cell wall turnover and autolysis by
vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J
Bacteriol 179:2557-2566.
143. Pantosti A, Sanchini A, Monaco M (2007). Mechanisms of antibiotic resistance in
staphylococcus aureus. Future Microbiol 2(3):323-334.
144. Cui L, Iwamoto A, Lian J-Q, et al. (2006). Novel mechanism of antibiotic
resistance originating in vancomycin-intermediate Staphylococcus aureus.
Antimicrob Agents Chemother 50:428-438.
145. Sakoulas G, Eliopoulos G, Moellering R, et al. (2003). Staphylococcus aureus
accessory gene regulator (agr) group II: is there a relationship to the development
of intermediate-level glycopeptide resistance? J Infect Dis 187:929-938.
146. Tsuji B, Rybak M, Lau K, Sakoulas G (2007). Evaluation of accessory gene
regulator (agr) group and function in the proclivity towards vancomycin
intermediate resistance in Staphylococcus aureus (VISA). Antimicrob Agents
Chemother 51:1089-1091.
147. Arthur M, Reynolds P, Courvalin P (1996). Glycopeptide resistance in enterococci.
Trends Microbiol. 4:401-407.
223
148. Weigel L, Clewell D, Gill S et al. (2003). Genetic analysis of a high-level
vancomycin-resistant isolate of Staphylococcus aureus. Science 302:1569-1571.
149. Weigel L, Donlan R, Shin D et al. (2007). High level vancomycin-resistant
Staphylococcus aureus isolates associated with a polymicrobial biofilm.
Antimicrob Agents Chemother 51:231-238.
150. Tenover F, Weigel L, Appelbaum P et al. (2004). Vancomycin-resistant
Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents
Chemother 48:275-280.
151. Zhu W, Weigel L, Clark N, McDougal L, Patel M (2006). Presented at: 46th
Interscience Conference for Antimicrobial Agents and Chemotherapy. San
Francisco, CA USA, 17-20.
152. Courvalin P (2006). Vancomycin resistance in Gram-positive cocci. Clin Infect Dis
42(Suppl. 1):S25-S34.
153. Hooper D (2002). Fluoroquinolone resistance among Gram-positive cocci. Lancet
Infect Dis 2:530-538.
154. Schmitz F, Jones M, Hofmann B et al. (1998). Characterization of grlA, grlB, gyrA,
and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects
of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother 42:1249-1252.
155. Kaatz GW, Seo SM, Ruble CA (1993). Efflux-mediated fluoroquinolone resistance
in Staphylococcus aureus. Antimicrob Agents Chemother 37:1086–1094.
156. Diekema DJ, Jones RN (2001). Oxazolidinone antibiotics. Lancet 358:1975-1982.
157. Marchese A, Schito GC (2001). The Oxazolidinone as a new family of
antimicrobial agent. Clin Microbiol Infect 7(4):66-74.
224
158. Pletz MW, Burkhardt O, Welte T (2010). Nosocomial methicillin-resistant
Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin?—
Comparision of pharmacology and clinical efficacy. Eur J Med Res 15:507-513.
159. Moellering RC (2003). Linezolid: the first oxazolidinone antimicrobial. Ann Intern
Med 138:135-142.
160. Meka VG, Pillai SK, Sakoulas G, et al. (2004). Linezolid resistance in sequential
Staphylococcus aureus isolates associated with a T2500A mutation in the 23S
rRNA gene and loss of a single copy of rRNA. J Infect Dis 190:311-317.
161. Morales G, Picazo JJ, Baos E, et al. (2010). Resistance to linezolid is mediated by
the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus
aureus. Clin Infect Dis 50:821-825.
162. Locke JB, Hilgers M, Shaw KJ (2009). Novel ribosomal mutations in
Staphylococcus aureus strains identified through selection with the oxazolidinones
linezolid and torezolid (TR-700). Antimicrob Agents Chemother 53:5265-5274.
163. Canu A, Leclercq R. (2009). Macrolides and lincosamides. In Mayers DL (ed)
Antimicrobial Drug Resistance. Mechanisms of drug resistance. Vol. 1. pp. 211-
221. Humana Press.
164. Tenover FC (2006). Mechanisms of antimicrobial resistance in bacteria. Am J
Med 119:S3-S10.
165. Schlünzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, and
Franceschi F (2001). Structural basis for the interaction of antibiotics with the
peptidyl transferase centre in eubacteria. Nature 413:814-821.
166. Polacek N, and Mankin AS (2005). The ribosomal peptidyl transferase center:
structure, function, evolution, inhibition. Crit Rev Biochem Mol Biol 40:285-311.
225
167. Courvalin P, Ounissi H, Arthur M (1985). Multiplicity of macrolide lincosamide–
streptogramin antibiotic resistance determinants. J Antimicrob Chemother 16(Suppl
A):91-100.
168. Leclercq R, Courvalin P (1991). Bacterial resistance to macrolide, lincosamide, and
streptogramin antibiotics by target modification. Antimicrob Agents Chemother
35:1267-1272.
169. Oliveira SS, Murphy E, Gamon MR, Bastos MC (1993). pRJ5: a naturally
occurring Staphylococcus aureus plasmid expressing constitutive macrolide-
lincosamide–streptogramin B resistance contains a tandem duplication in the leader
region of the ermC gene. J Gen Microbiol 139(Pt 7):1461-1467.
170. Catchpole I, Dyke KG (1990). A Staphylococcus aureus plasmid that specifies
constitutive macrolide-lincosamide–streptogramin B resistance contains a novel
deletion in the ermC attenuator. FEMS Microbiol Lett 57:43-47.
171. Weisblum B (1985). Inducible resistance to macrolides, lincosamides and
streptogramin type B antibiotics: the resistance phenotype, its biological diversity,
and structural elements that regulate expression–a review. J Antimicrob Chemother
16:63-90.
172. Weisblum B (1995). Insights into erythromycin action from studies of its activity
as inducer of resistance. Antimicrob Agents Chemother 39:797-805.
173. Clarebout G, Nativelle E, Leclercq R (2001). Unusual inducible cross resistance to
macrolides, lincosamides, and streptogramins B by methylase production in clinical
isolates of Staphylococcus aureus. Microb Drug Resist 7:317-322.
174. Siberry GK, Tekle T, Carroll K, Dick J (2003). Failure of clindamycin treatment of
methicillin-resistant Staphylococcus aureus expressing inducible clindamycin
resistance in vitro. Clin Infect Dis 37:1257-1260.
226
175. Ross JI, Eady EA, Cove JH, Cunliffe WJ, Baumberg S, Wootton JC (1990).
Inducible erythromycin resistance in staphylococci is encoded by a member of the
ATP-binding transport super-gene family. Mol Microbiol 4:1207-1214.
176. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J (1999).
Distribution of genes encoding resistance to macrolides, lincosamides, and
streptogramins among staphylococci. Antimicrob Agents Chemother 43:1062-1066.
177. Brisson-Noel A, Delrieu P, Samain D, Courvalin P (1988). Inactivation of
lincosaminide antibiotics in Staphylococcus. Identification of lincosaminide O-
nucleotidyltransferases and comparison of the corresponding resistance genes. J
Biol Chem 263:15880-15887.
178. Allignet J, Loncle V, el Sohl N (1992). Sequence of a staphylococcal plasmid gene,
vga, encoding a putative ATP-binding protein involved in resistance to
virginiamycin A-like antibiotics. Gene 117:45-51.
179. Allignet J, El Solh N (1997). Characterization of a new staphylococcal gene, vgaB,
encoding a putative ABC transporter conferring resistance to streptogramin A and
related compounds. Gene 202:133-138.
180. Allignet J, Liassine N, el Solh N (1998). Characterization of a staphy lococcal
plasmid related to pUB110 and carrying two novel genes, vatC and vgbB, encoding
resistance to streptogramins A and B and similar antibiotics. Antimicrob Agents
Chemother 42:1794-1798.
181. Allignet J, Loncle V, Simenel C, Delepierre M, Solh N (1993). Sequence of a
staphylococcal gene, vat, encoding an acetyltransferase inactivating the A-type
compounds of virginiamycin-like antibiotics. Gene 130:91-98.
182. Allignet J, Solh N (1995). Diversity among the gram-positive acetyltransferases
inactivating streptogramin A and structurally related compounds and
227
characterization of a new staphylococcal determinant, vatB. Antimicrob Agents
Chemother 39:2027-2036.
183. Mukhtar TA, Koteva KP, Hughes DW, Wright GD (2001). Vgb from
Staphylococcus aureus inactivates streptogramin B antibiotics by an elimination
mechanism not hydrolysis. Biochemistry 40:8877-8886.
184. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ (2004). Quinupristin–
dalfopristin resistance in gram-positive bacteria: mechanism of resistance and
epidemiology. Clin Infect Dis 38:92-98.
185. Fantin B, Leclercq R, Merle Y, et al. (1995). Critical influence of resistance to
streptogramin B-type antibiotics on activity of RP 59500 (quinupristin–
dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
Antimicrob Agents Chemother 39:400-405.
186. Landy M, Larkum NW, Oswald EJ, Streighoff P (1943). Increased synthesis of p-
amino-benzoic acid associated with the development of sulfonamide resistance in
Staphylococcus aureus. Science 97:265-267.
187. Then RL, Kohl I, Burdeska A (1992). Frequency and transferability of
trimethoprim and sulfonamide resistance in methicillin-resistant Staphylococcus
aureus and Staphylococcus epidermidis. J Chemother 4:67-71.
188. Hampele IC, D’Arcy A, Dale GE, et al. (1997). Structure and function of the
dihydropteroate synthase from Staphylococcus aureus. J Mol Biol 268:21-30.
189. Dale GE, Broger C, Hartman PG, et al. (1995). Characterization of the gene for the
chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermidis
ATCC 14990: the origin of the trimethoprim-resistant S1 DHFR from
Staphylococcus aureus? J Bacteriol 177:2965-2970.
228
190. Dale GE, Broger C, D’Arcy A, et al. (1997). A single amino acid substitution in
Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance.
J Mol Biol 266:23-30.
191. Davies J, Gorini L, Davis BD (1965). Misreading of RNA codewords induced by
aminoglycoside antibiotics. Mol Pharmacol 1:93–106.
192. Shaw KJ, Rather PN, Hare RS, Miller GH (1993). Molecular genetics of
aminoglycoside resistance genes and familial relationships of the aminoglycoside-
modifying enzymes. Microbiol Rev 57:138–163.
193. Lyon BR, Skurray R (1987). Antimicrobial resistance of Staphylococcus aureus:
genetic basis. Microbiol Rev 51:88–134.
194. Daigle DM, Hughes DW, Wright GD (1999). Prodigious substrate specificity of
AAC(6′)-APH (2″), an aminoglycoside antibiotic resistance determinant in
enterococci and staphylococci. Chem Biol 6:99-110.
195. Trzcinski K, Cooper BS, Hryniewicz W, Dowson CG (2000). Expression of
resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother 45:763–770.
196. Nesin M, Svec P, Lupski JR, et al. (1990). Cloning and nucleotide sequence of a
chromosomally encoded tetracycline resistance determinant, tetA(M), from a
pathogenic, methicillin-resistant strain of Staphylococcus aureus. Antimicrob
Agents Chemother 34:2273-2276.
197. Bismuth R, Zilhao R, Sakamoto H, Guesdon JL, Courvalin P (1990). Gene
heterogeneity for tetracycline resistance in Staphylococcus spp. Antimicrob Agents
Chemother 34:1611-1614.
198. Burdett V (1993). tRNA modification activity is necessary for Tet(M)-mediated
tetracycline resistance. J Bacteriol 175:7209-7215.
229
199. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H,
MacKenzie FM (2012). Meticillin-resistant Staphylococcus aureus (MRSA): global
epidemiology and harmonisation of typing methods. Int J Antimicrob Agents
39:273–282.
200. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D,
Friedrich AW (2010). Geographic distribution of Staphylococcus aureus causing
inva-sive infections in Europe: a molecular-epidemiological analysis. PLoS Med
7:e1000215.
201. Song JH, Hsueh PR, Chung DR, Ko KS, Kang CI, Peck KR, et al. (2011). Spread
of methicillin-resistant Staphylococcus aureus between the community and the
hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother 66:1061-
9.
202. European Centre for Disease Prevention and Control (2010). Antimicrobial
resistance surveillance in Europe 2009. Annual report of the European
Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden:
ECDC.
203. Mejía C, Zurita J, Guzmán-Blanco M (2010). Epidemiology and surveillance of
methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis
14(Suppl. 2):S79-86.
204. Joshi S, Ray P, Manchanda V, Bajaj J, Chitnis DS, Gautam V et al. (2013).
Methicillin resistant Staphylococcus aureus in India: Prevalence and susceptibility
pattern. Indian J Med Res 137:363-369.
205. Pulimood TB, Lalitha MK, Jesudson MV, Pandian R, Selwyn JJ (1996). The
spectrum of antimicrobial resistance among methicillin resistant Staphylococcus
aureus (MRSA) in a tertiary centre in India. Indian J Med Res 103:212-215.
230
206. Khadri H, Alzohairy M (2010). Prevalence & antibiotic susceptibility pattern of
methicillin resistance and coagulase‐negative staphylococci in a tertiary hospital in
India. International J Med Med Sci 2:116‐120.
207. Dar JA, Thoker MA, Khan JA, Ali A, Khan MA, Rizwan M, Bhat KH, Dar MJ,
Ahmed N, Ahmad S (2006). Molecular epidemiology of clinical and carrier strains
of methicillin resistant Staphylococcus aureus (MRSA) in the hospital settings of
North India. Annual Clin Microbiol Antimicrob 5(1):22-25.
208. Anupurba S, Sen MR, Nath G, Sharma BM, Gulati AK, Mohapatra TM (2003).
Prevalence of methicillin resistant Staphylococcus aureus in a tertiary care referral
hospital in eastern Uttar Pradesh. Indian J Med Microbiol 21:49‐51.
209. Chakravarthy A, Talwar V, Gupta H (1988). Antibiotic resistant pattern of
Staphylococcus aureus with special reference to methicillin resistant strains. Indian
J Med Res 87:576-579.
210. Mehta AA, Rodrigues CC, Kumar RR, Rattan AA, Sridhar HH, Mattoo VV, Ginde
VV (1996). A pilot programme of MRSA surveillance in India. (MRSA
Surveillance Study Group). J Postgrad Med 42(1):1-3.
211. Tyagi A, Kapil A, Singh P (2008). Incidence of methicillin resistant
Staphylococcus aureus (MRSA) in pus samples at a tertiary care hospital. JIACM
9:33–35.
212. Majumder D, Bardoloi SJN, Phukan AC, Mahanta J (2001). Antimicrobial
susceptibility pattern among methicillin resistant Staphylococcus isolates in Assam.
Indian J Med Microbiol 19:138-40.
213. Saikia L, Nath R, Choudhury B, Sarkar M (2009). Prevalence and antimicrobial
susceptibility pattern of methicillin resistant Staphylococcus aureus in Assam.
Indian J Critic Care Med 13:156‐158.
231
214. Pal N, Ayyagari A (1991). Drug resistance pattern of methicillin resistant
Staphylococcus aureus. Indian Paediatrics 28:731-733.
215. Arora S, Devi P, Arora U, Devi B (2010). Prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) in a tertiary care hospital in North India. J Lab
Physicians 2(2):78-81.
216. Rao BN, Prabhakar T (2011). Prevalence and antimicrobial susceptibility pattern of
methicillin resistant Staphylococcus aureus (MRSA) in and around
Visakhapatnam, Andhra Pradesh, India . JPBMS 4(3):1-5.
217. Hanumantappa AR, Chandrappa NR, Rajasekharappa MG (2003). Prevalence of
methicillin resistant Staphylococcus in Karnataka. Indian J Pathol, Microbiol
46:129-132.
218. Nishi V, Raman BR, Yengkokpam C, Bhat GK (2004). Simple broth disc technique
for the detection of MRSA, Indian J Med Microbiol 22:69-70.
219. Rajaduraipandi K, Mani KR, Panneerselvam K, Mani M, Bhaskar M, Manikandan
P (2006). Prevalence and antimicrobial susceptibility pattern of methicillin resistant
Staphylococcus aureus: A multicentre study. Indian J Med Microbiol 24:34-38.
220. Murugan S, Mani KR, Uma Devi P (2008). Prevalence of methicillin resistant
Staphylococcus aureus among diabetes patients with foot ulcers and their
antimicrobial susceptibility pattern. J Clin Diag Res 2:979‐984.
221. Kumar S, Joseph N, Easow J, Singh R et al. (2012). Prevalence and current
antibiogram of staphylococci isolated from various clinical specimens in a tertiary
care hospital in Pondicherry. The Internet Journal of Microbiology 10(1).
http://ispub.com/IJMB/10/1/13868
222. Weist K, Cimbal AK, Lecke C, Kampf G, Rüden H, Vonberg R (2006). Evaluation
of six agglutination tests for Staphylococcus aureus identification depending upon
232
local prevalence of meticillin-resistant S. aureus (MRSA). J Med Microbiol
55:283-290.
223. Swenson JM, Spargo J, Tenover FC, FerraroM J (2001) Optimal inoculation
methods and quality control for the NCCLS oxacillin agar screen test for detection
of oxacillin resistance in Staphylococcus aureus. J Clin Microbiol 39:3781‐3784.
224. Anand KB, Agrawal P, Kumar S, Kapila K (2009) Comparison of cefoxitin disk
diffusion test, oxacillin screen agar, and PCR for mecA gene for detection of
MRSA. Indian J Med Microbiol 27:27‐29.
225. Boubaker IB, Abbes RB, Abdallah HB, Mamlouk K, Mahjoubi F, Kammoun A,
Hammami A, Redjeb SB (2004). Evaluation of a cefoxitin disk diffusion test for
the routine detection of methicillinresistant Staphylococcus aureus. Clin Microbiol
Infect 10:762-765.
226. Fernandes CJ, Fernandes LA, Collignon P (2005). Cefoxitin resistance as a
surrogate marker for the detection of methicillin-resistant Staphylococcus aureus. J
Antimicrob Chemother 55:506-510.
227. Brown DFJ, Brown L (1991). Evaluation of the E test, a novel method of
quantifying antimicrobial activity. J Antimicrob Chemother 27:185-190.
228. Huang MB, Baker CN, Banerjee S, Tenover FC (1992).Accuracy of the E test for
determining antimicrobial susceptibilities of Staphylococci, Enterococci,
Campylobacter jejuni, and Gram-negative bacteria resistant to antimicrobial agents.
J Clin Microbiol 30: 3243-3248.